The treatment of obesity with EA, which was employed to reduce methylation Tsc1 and inhibit the activity of mTORC1, thereby controlling appetite-regulating factors (e.g., NPY, AgRP, and PoMC) and mitigating obesity. Here, NPY is linked to obesity due to melanocortin 4 receptor deficiency.